FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit... June 17, 2021 Load more HOT NEWS Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining Fisioterapeutas en oncología Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with...
